Antiasthmatic
PreclinicalSmall molecule
Antiasthmatic is one of 13 small molecule programs targeting Nasal polyposis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Nasal Polyposis
#DrugCompanyPhaseTrials
1Xolair
RochePhase 3
Fasenra
AstraZenecaPhase 3
Nucala
GGlaxo Dba Glaxosmithkline
Phase 2
Kenalog
BBassett Healthcare
Phase 2
Fevipiprant
NovartisPhase 3
Administration of Cimzia
UUniversity Hospital, Ghent
Phase 2
Asmanex
NovartisPreclinical
Run in Medication
GSKPhase 2
Prevacid
TakedaPreclinical
Flovent
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Nasal polyposis1 trial
Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry
Unknown status·IInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz··NCT06163807·1,200 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antiasthmatic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details